16 DecAgios Pharmaceuticals to present AG-221 Phase 1 study results at EHA meeting Agios Pharmaceuticals.

Title: A Phase I Research of AG-221, an initial in Class, Powerful Inhibitor of the IDH2-Mutant Protein, in Patients with IDH2 Mutant Positive Advanced Hematologic Malignancies Demonstration time: Saturday, June 14 at 1:30 p.m. CEST Session title: Later breaking1 Presenter: Stephane De Botton, M.D., Institut de Cancerologie Gustave Roussy, Villejuif, France Abstract code: LB2434 Conference Call Information Agios will sponsor a conference contact and webcast on Monday, June 16, 2014, at 8:30 a.m. EDT to examine the clinical data shown at EHA from the ongoing Phase 1 study of AG-221.Â.. Agios Pharmaceuticals to present AG-221 Phase 1 study results at EHA meeting Agios Pharmaceuticals, Inc. , a head in the areas of cancer rate of metabolism and inborn errors of metabolism , announced that new clinical data from the Phase 1 research of AG-221 today, an available orally, selective, potent inhibitor of the mutated IDH2 proteins, will be highlighted in an oral display at the 19th Congress of the European Hematology Association occurring June 12 -15, 2014 in Milan, Italy.Although Caz knew lots of things about her adoptive family, she realized that she knew nothing about the social people whose genes she shared. It’s natural for those who are adopted to wonder about their birth households and where they originated from. This curiosity often becomes more intense as part of the procedure of self-discovery that happens through the teenage years. There are health reasons Sometimes, or other important reasons, for searching for one’s birth family.